Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of March 2025, specifically reporting on a transaction executed on March 3, 2025. The Company, a foreign private issuer based in Jerusalem, Israel, entered into a Standby Equity Purchase Agreement (the "Purchase Agreement") with YA II PN, LTD. ("Yorkville"), a Cayman Islands exempt limited partnership.
Key Financial Metrics and Transaction Terms
- Commitment Amount: Up to $10.0 million in American Depositary Shares (ADSs).
- Term: 36 months from the execution date.
- Pricing Mechanism: ADSs sold to Yorkville will be priced at 97% of the lowest daily Volume Weighted Average Price (VWAP) during the three consecutive trading days following the delivery of an Advance Notice.
- Ownership Cap: Yorkville's purchases are limited to prevent beneficial ownership from exceeding 9.99% of the Company's outstanding voting power.
- Immediate Costs: The Company issued 28,784 Commitment ADSs to Yorkville and paid a $15,000 structuring fee.
- Liquidity Impact: The filing does not provide specific cash flow, revenue, or debt figures for the period; it focuses solely on the financing arrangement.
Material Changes and Conditions
The primary material change is the establishment of a committed capital source. The issuance of Commitment ADSs is structured in two equal installments of 14,392 ADSs each. The first installment was issued on or about the execution date, while the second is due upon the earlier of the first issuance of Advance ADSs or 90 calendar days after the relevant SEC Registration Statement is declared effective. The agreement is contingent upon the effectiveness of a registration statement filed with the SEC.
Outlook, Risks, and Management Commentary
Management views this agreement as a mechanism to secure flexible access to capital. However, the filing includes standard forward-looking statement warnings, noting that future events may differ from expectations. Key risks and contingencies include:
- Regulatory Risk: The agreement is subject to the SEC declaring the Registration Statement effective.
- Market Risk: The Company may specify a minimum acceptable price per ADS, which could limit the ability to draw funds if market prices fall below this threshold.
- Dilution: The issuance of Commitment ADSs and potential future Advance ADSs will result in shareholder dilution.
- Investor Status: Yorkville is an accredited investor acquiring shares for investment purposes, not for resale.
Investor Verification Checklist
- Verify the status of the SEC Registration Statement required to activate the Purchase Agreement.
- Review the full text of the Standby Equity Purchase Agreement (Exhibit 99.1) for specific covenants and termination rights.
- Monitor the Company's stock price relative to the 97% VWAP pricing formula to assess potential dilution costs.
- Confirm the exact date of issuance for the second tranche of Commitment ADSs.
- Check subsequent filings for any actual "Advances" drawn under the $10.0 million commitment.